May 01 2024
Now enrolling: Vibrance-1 clinical study for narcolepsy type 1
h in Clinical Trial
Researchers are looking for adults 18-70 years of age with a diagnosis of narcolepsy type 1 (NT1) to take part in the Vibrance-1 Study. The purpose of this study is to research the safety and effectiveness of an investigational study drug taken orally once daily and how it may work in adults with NT1. Individuals with NT1 may be eligible for the Vibrance-1 Study. Orexin is a chemical in the brain that helps regulate the sleep/wake cycle. The investigational study drug, ALKS 2680, is an orexin-2 receptor agonist and may improve symptoms of sleep disorder, such as excessive daytime sleepiness (EDS) and cataplexy, in patients with NT1.
Individuals will be evaluated by the study team to determine their eligibility to participate in this research. Each individual who qualifies will receive either the study drug or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. Compensation for time and travel may also be available.
To learn more:
- Visit VibranceStudies.com
CTR-003484